US86627T1088
© BusinessWire
05.12.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 67,483 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2025
SMMT
LISTED
NASDAQ
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial, conducted in China and sponsored by Akeso, featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics to Present at Upcoming Investor Conferences
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the Summit leadership team will participate in fireside chats and individual investor meetings at the following conferences:
UBS Glo...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
31.10.2025
SMMT
LISTED
NASDAQ
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that results from the Phase III HARMONi-A trial, conducted in China and sponsored by our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
22.10.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Raises $500 Million in Private Placement
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company has accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of approximately 26.68 million shares of the Company’s common stock at $18.74 per share, the closing price on Tuesday, October...
Themefolio
Profiler
Peergroup
© BusinessWire
20.10.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter ended September 30, 2025.
Planned BLA Submission for Ivonescimab in Q4 2025
Today, Summit announces that, based on the results of the HARMONi clinical trial, it plan...
Themefolio
Profiler
Peergroup
© BusinessWire
19.10.2025
SMMT
LISTED
NASDAQ
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as par...
Themefolio
Profiler
Peergroup
© BusinessWire
17.10.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer (CRC) with the initiation of the global Phase III HARMONi-GI3 trial.
Summit is start...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the market opens. The ESMO data relates to the planned disclosure of the HARMONi-6 clinical trial data.
As a reminder, the Phase III HARMONi-6 trial, conducted in China and s...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced the grant of inducement awards of options to purchase a collective total of up to 65,750 shares of common stock. Awards were made to eight new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
SMMT
LISTED
NASDAQ
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be featured as part of the P...
Themefolio
Profiler
Peergroup
© BusinessWire
07.09.2025
SMMT
LISTED
NASDAQ
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented this morning as part of the Presidential Symposium at the International Association for the Study of...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
03.09.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host a call to discuss the ivonescimab data from our global Phase III clinical trial, HARMONi, presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer’s (IASLC) 2025 World Conference on Lung Cancer (WCLC 2025) in Ba...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2025
SMMT
LISTED
NASDAQ
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer’s...
Themefolio
Profiler
Peergroup
© BusinessWire
14.07.2025
SMMT
LISTED
NASDAQ
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Summit Therapeutics Inc. (“Summit” or “the Company”) (NASDAQ: SMMT) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
SMMT
LISTED
NASDAQ
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
News Preview
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of...
Themefolio
Profiler
Peergroup
© BusinessWire
06.06.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 71,275 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 9, 2025, at 1:20 PM ET. Members of the Summit management team will participate in a fireside chat presentation providing a...
Themefolio
Profiler
Peergroup
© BusinessWire
30.05.2025
SMMT
LISTED
NASDAQ
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab, successfully met the progression-free survival (PFS) primary endpoint and showed a positive trend in the other primary endpoint, overall surv...
Themefolio
Profiler
Peergroup
© BusinessWire
16.05.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 94,050 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2025.
Operational & Corporate Updates
Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class...
Themefolio
Profiler
Peergroup
© BusinessWire
25.04.2025
SMMT
LISTED
NASDAQ
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by the Chinese Health Authorities, the National Medical Products Administration (NMPA), for a second indication based on the results of the Phase III clinical trial, HARMONi-2 o...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes.
Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be...
Themefolio
Profiler
Peergroup
© BusinessWire
23.04.2025
SMMT
LISTED
NASDAQ
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, HARMONi-6 or AK112-306, met its primary endpoint of progression-free survival (PFS). HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy com...
Themefolio
Profiler
Peergroup
© BusinessWire
04.04.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 176,915 shares of common stock. Awards were made to ten (10) new employees of the Company. The awards were granted as an inducement material to the new employees becoming emplo...
Themefolio
Profiler
Peergroup
© BusinessWire
21.03.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 147,500 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employee...
Themefolio
Profiler
Peergroup
© BusinessWire
17.03.2025
SMMT
LISTED
NASDAQ
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately.
Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics,...
Themefolio
Profiler
Peergroup
© BusinessWire
14.03.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 122,650 shares of common stock. Awards were made to 12 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees o...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on operational progress for the fourth quarter and year-ended December 31, 2024.
Operational & Corporate Updates
Operational progress continues with ivonescimab (SMT112), an investigational, potentially firs...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer’s antibody drug conjugates (ADCs) across multiple solid tumor settings.
“Rapidly developing novel mechanisms t...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2024 financial results and provide an operational update for the Company on Monday, February 24, 2025, before the market opens.
Summit will host a live webcast of the earnings conference call at 9:00am...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 116,725 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 145,550 shares of common stock. Awards were made to nine new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
SMMT
LISTED
NASDAQ
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 13, 2025 at 3:00 PM PT. Robert W. Duggan, Chairman and Chief Executive Officer, and Dr. Maky Zanganeh, Chief Executi...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2024
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 98,000 shares of common stock. Awards were made to six new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees o...
Themefolio
Profiler
Peergroup
© BusinessWire
26.11.2024
SMMT
LISTED
NASDAQ
Summit Therapeutics to Present at Upcoming Investor Conferences
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 7th Annual Evercore HealthCONx Conference and Citi’s 2024 Global Healthcare Conference, both being held in Miami. Our management team will participate in fireside chats surrounding the development of our innovat...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 227,600 shares of common stock. Awards were made to 15 new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees o...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2024
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reported an update on its operational progress and financial results for the third quarter and nine months ended September 30, 2024.
Operational & Corporate Updates
Our operational progress continues with ivonescimab (SMT112), an investigational, potentially fir...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
SMMT
LISTED
NASDAQ
Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its third quarter 2024 financial results and provide an operational update for the Company on Wednesday, October 30, 2024, before the market opens.
Summit will host a live webcast of the earnings conference call at 9:00am ET, which wi...
Themefolio
Profiler
Peergroup
© BusinessWire
04.10.2024
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 249,550 shares of common stock. Awards were made to ten new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2024
SMMT
LISTED
NASDAQ
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that we have completed enrollment in our HARMONi clinical trial, a multi-regional Phase III study sponsored by Summit evaluating ivonescimab plus platinum-doublet chemotherapy vs. placebo plus platinum-doublet chemotherapy with epidermal growth factor recept...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2024
SMMT
LISTED
NASDAQ
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented at the 2024 European Society for Medical Oncology Annual Meeting (ESMO 2024) in Barcelona, Spain, including two presentations and one poster fea...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2024
SMMT
LISTED
NASDAQ
Summit Therapeutics Raises $235 Million
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of approximately 10.35 million shares of the Company’s common stock at $22.70 per share, the closing price on Wednesday, September...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2024
SMMT
LISTED
NASDAQ
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented this morning as part of the Presidential Symposium at the International Ass...
Themefolio
Profiler
Peergroup
© BusinessWire
06.09.2024
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 102,000 shares of common stock. Awards were made to five new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees...
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2024
SMMT
LISTED
NASDAQ
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the primary analysis of the Phase III HARMONi-2 trial featuring its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Presidential Symposium at the International Association for the Study...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2024
SMMT
LISTED
NASDAQ
Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
News Preview
First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLCIvonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLCHONG KONG, Aug. 11, 2024 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) ("Akeso,") today announced two upcom...
Themefolio
Profiler
Peergroup
© BusinessWire
09.08.2024
SMMT
LISTED
NASDAQ
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 453,250 shares of common stock. Awards were made to fourteen new employees of the Company. The awards were granted as an inducement material to the new employees becoming emplo...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
